Background: Fisetin is commonly used as an anti-inflammatory and neuroprotective drug. In this study, we aimed to investigate the efficacy of fisetin in alleviating intracerebral hemorrhage (ICH)-induced brain injury. Methods: Mouse ICH models were constructed using the collagenase-induction method. ICH mice received fisetin treatment at the dose of 10–90 mg/kg, followed by the evaluation of neurological deficit through neurologic severity scores (mNSS), brain water content and terminal deoxynucleotidyl transferase dUTP nick end labeling analysis of cell apoptosis. Cytokine levels were also assessed with enzyme-linked immunosorbent assay. The activation of astrocytes and microglia was evaluated through S100 staining and Western blot analysis of ionized calcium-binding adaptor molecule 1 respectively. Nuclear factor kappa-B (NF-κB) signaling was also evaluated by Western blot. Results: ICH mice demonstrated dramatic increase in mNSS, brain edema and cell apoptosis, indicating severe brain deficit. Fisetin treatment lowered these parameters, suggesting the alleviation of brain injury. Levels of proinflammatory cytokines were reduced, accompanied by a prominent decrease in activated astrocytes and microglia. NF-κB signaling was also attenuated by fisetin treatment. Conclusion: Fisetin effectively alleviates ICH by downregulating proinflammatory cytokines and attenuating NF-κB signaling. These data suggest fisetin as a valuable natural flavonol for clinical management of ICH-induced brain injury.

1.
Zhou Y, Wang Y, Wang J, Anne Stetler R, Yang QW: Inflammation in intracerebral hemorrhage: From mechanisms to clinical translation. Prog Neurobiol 2014; 115: 25–44.
2.
Becker KJ, Baxter AB, Cohen WA, Bybee HM, Tirschwell DL, Newell DW, Winn HR, Longstreth WT Jr: Withdrawal of support in intracerebral hemorrhage may lead to self-fulfilling prophecies. Neurology 2001; 56: 766–772.
3.
Hemphill JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH: Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke 2015; 46: 2032–2060.
4.
Karve IP, Taylor JM, Crack PJ: The contribution of astrocytes and microglia to traumatic brain injury. Br J Pharmacol 2016; 173: 692–702.
5.
Zhang YF, Yi B, Ma J, Zhang L, Zhang H, Yang Y, Dai Y: Quercetin promotes neuronal and behavioral recovery by suppressing inflammatory response and apoptosis in a rat model of intracerebral hemorrhage. Neurochem Res 2015; 40: 195–203.
6.
Kang DW, Kim CK, Jeong HG, Soh M, Kim T, Choi IY, Ki SK, Kim DY, Yang W, Hyeon T, Lee SH: Biocompatible custom ceria nanoparticles against reactive oxygen species resolve acute inflammatory reaction after intracerebral hemorrhage. Nano Res 2017; 10: 2743–2760.
7.
Benavente-Garcia O, Castillo J: Update on uses and properties of citrus flavonoids: New findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 2008; 56: 6185–6205.
8.
Perez-Vizcaino F, Duarte J: Flavonols and cardiovascular disease. Mol Aspects Med 2010; 31: 478–494.
9.
Maher P, Dargusch R, Ehren JL, Okada S, Sharma K, Schubert D: Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. PLoS One 2011; 6:e21226.
10.
Patel MY, Panchal HV, Ghribi O, Benzeroual KE: The neuroprotective effect of fisetin in the mptp model of parkinson’s disease. J Parkinsons Dis 2012; 2: 287–302.
11.
Aggarwal BB, Sung B, Gupta SC: Inflammation and Cancer. New York, Springer, 2014.
12.
Khan N, Afaq F, Syed DN, Mukhtar H: Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer lncap cells. Carcinogenesis 2008; 29: 1049–1056.
13.
de Sousa RR, Queiroz KC, Souza AC, Gurgueira SA, Augusto AC, Miranda MA, Peppelenbosch MP, Ferreira CV, Aoyama H: Phosphoprotein levels, mapk activities and nfkappab expression are affected by fisetin. J Enzyme Inhib Med Chem 2007; 22: 439–444.
14.
Hijioka M, Matsushita H, Ishibashi H, Hisatsune A, Isohama Y, Katsuki H: α7 nicotinic acetylcholine receptor agonist attenuates neuropathological changes associated with intracerebral hemorrhage in mice. Neuroscience 2012; 222: 10–19.
15.
Li Y, Chen J, Wang L, Lu M, Chopp M: Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology 2001; 56: 1666–1672.
16.
Ono R, Kaisho T, Tanaka T: Pdlim1 inhibits NF-κb-mediated inflammatory signaling by sequestering the p65 subunit of NF-κb in the cytoplasm. Sci Rep 2015; 5: 18327.
17.
Wu H, Wu T, Han X, Wan J, Jiang C, Chen W, Lu H, Yang Q, Wang J: Cerebroprotection by the neuronal pge2 receptor ep2 after intracerebral hemorrhage in middle-aged mice. J Cereb Blood Flow Metab 2017; 37: 39–51.
18.
Zhou CH, Wang CX, Xie GB, Wu LY, Wei YX, Wang Q, Zhang HS, Hang CH, Zhou ML, Shi JX: Fisetin alleviates early brain injury following experimental subarachnoid hemorrhage in rats possibly by suppressing tlr 4/NF-κb signaling pathway. Brain Res 2015; 1629: 250–259.
19.
Ragelle H, Crauste-Manciet S, Seguin J, Brossard D, Scherman D, Arnaud P, Chabot GG: Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm 2012; 427: 452–459.
20.
Maher P: Protective effects of fisetin and other berry flavonoids in parkinson’s disease. Food Funct 2017; 8: 3033–3042.
21.
Kampkotter A, Gombitang Nkwonkam C, Zurawski RF, Timpel C, Chovolou Y, Watjen W, Kahl R: Effects of the flavonoids kaempferol and fisetin on thermotolerance, oxidative stress and foxo transcription factor daf-16 in the model organism caenorhabditis elegans. Arch Toxicol 2007; 81: 849–858.
22.
Zhou QB, Jin YL, Jia Q, Zhang Y, Li LY, Liu P, Liu YT: Baicalin attenuates brain edema in a rat model of intracerebral hemorrhage. Inflammation 2014; 37: 107–115.
23.
Sandireddy R, Yerra VG, Komirishetti P, Areti A, Kumar A: Fisetin imparts neuroprotection in experimental diabetic neuropathy by modulating Nrf2 and NF-κb -pathways. Cell Mol Neurobiol 2016; 36: 883–892.
24.
Wang CY, Mayo MW, Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappab. Science 1996; 274: 784–787.
25.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461–466.
26.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073–1081.
27.
Arora R, Yates C, Gary BD, McClellan S, Tan M, Xi Y, Reed E, Piazza GA, Owen LB, Dean-Colomb W: Panepoxydone targets NF-kB and foxm1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer. PLoS One 2014; 9:e98370.
28.
Spanos JP, Hsu NJ, Jacobs M: Microglia are crucial regulators of neuro-immunity during central nervous system tuberculosis. Front Cell Neurosci 2015; 9: 182.
29.
Jiang W, Wang Y, Sun W, Zhang M: Morin suppresses astrocyte activation and regulates cytokine release in bone cancer pain rat models. Phytother Res 2017; 31: 1298–1304.
30.
Baeuerle PA, Baichwal VR: Nf-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997; 65: 111–137.
31.
Rathee P, Chaudhary H, Rathee S, Rathee D, Kumar V, Kohli K: Mechanism of action of flavonoids as anti-inflammatory agents: a review. Inflamm Allergy Drug Targets 2009; 8: 229–235.
32.
Ali T, Badshah H, Kim TH, Kim MO: Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via rage/NF-kB/JNK signaling pathway in aging mouse model. J Pineal Res 2015; 58: 71–85.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.